Marc Blondel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9525700/publications.pdf

Version: 2024-02-01

74	2,785	201575	189801
papers	citations	27 h-index	50 g-index

77	77	77	3468
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nature Biotechnology, 2003, 21, 1075-1081.	9.4	168
2	Control of Nutrient-Sensitive Transcription Programs by the Unconventional Prefoldin URI. Science, 2003, 302, 1208-1212.	6.0	164
3	Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell, 2018, 5, 4-31.	1.4	158
4	The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO Journal, 2000, 19, 5362-5375.	3.5	154
5	Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. DMM Disease Models and Mechanisms, 2015, 8, 509-526.	1.2	115
6	Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. EMBO Journal, 2000, 19, 6085-6097.	3.5	108
7	Degradation of Hof1 by SCFGrr1 is important for actomyosin contraction during cytokinesis in yeast. EMBO Journal, 2005, 24, 1440-1452.	3.5	104
8	Mitochondrial ATP synthase disorders: Molecular mechanisms and the quest for curative therapeutic approaches. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 186-199.	1.9	99
9	Antihypertensive Drug Guanabenz Is Active In Vivo against both Yeast and Mammalian Prions. PLoS ONE, 2008, 3, e1981.	1.1	98
10	Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA. Nature Communications, 2017, 8, 16043.	5.8	94
11	Nuclear export of Far1p in response to pheromones requires the export receptor Msn5p/Ste21p. Genes and Development, 1999, 13, 2284-2300.	2.7	90
12	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene, 2004, 23, 4400-4412.	2.6	86
13	Cytotoxicity of diatom-derived oxylipins in organisms belonging to different phyla. Journal of Experimental Biology, 2004, 207, 2935-2946.	0.8	81
14	A yeast-based assay identifies drugs active against human mitochondrial disorders. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11989-11994.	3.3	73
15	Protein Folding Activity of Ribosomal RNA Is a Selective Target of Two Unrelated Antiprion Drugs. PLoS ONE, 2008, 3, e2174.	1.1	61
16	Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnology Journal, 2007, 2, 68-75.	1.8	57
17	Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 1105-1112.	0.5	54
18	<scp>The importance of naturally attenuated SARSâ€CoV</scp>â€2<scp>in the fight against COVID</scp>â€19. Environmental Microbiology, 2020, 22, 1997-2000.	1.8	54

#	Article	IF	Citations
19	A yeast-based assay to isolate drugs active against mammalian prions. Methods, 2006, 39, 72-77.	1.9	47
20	EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. Cancers, 2018, 10, 109.	1.7	47
21	G2 cyclins are required for the degradation of G1 cyclins in yeast. Nature, 1996, 384, 279-282.	13.7	46
22	Antiprion drugs 6â€aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Molecular Medicine, 2011, 3, 35-49.	3.3	41
23	Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a. Human Molecular Genetics, 2019, 28, 1561-1577.	1.4	41
24	Novel cationic bis(acylhydrazones) as modulators of Epsteinâ€“Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA. European Journal of Medicinal Chemistry, 2019, 178, 13-29.	2.6	35
25	The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget, 2016, 7, 69549-69564.	0.8	33
26	Epsteinâ€“Barr virusâ€encoded <scp>EBNA1</scp> and <scp>ZEBRA</scp>: targets for therapeutic strategies against <scp>EBV</scp>â€carrying cancers. Journal of Pathology, 2015, 235, 334-341.	2.1	31
27	Using budding yeast to screen for anti-prion drugs. Biotechnology Journal, 2006, 1, 58-67.	1.8	30
28	Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nature Communications, 2014, 5, 5585.	5.8	29
29	The Antiprion Compound 6-Aminophenanthridine Inhibits the Protein Folding Activity of the Ribosome by Direct Competition. Journal of Biological Chemistry, 2013, 288, 19081-19089.	1.6	26
30	The Toll-Like Receptor Agonist Imiquimod Is Active against Prions. PLoS ONE, 2013, 8, e72112.	1.1	26
31	Structureâ€“Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost Î±2-Adrenergic Receptor Agonistic Activity. ACS Chemical Neuroscience, 2014, 5, 1075-1082.	1.7	25
32	Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides. Nucleic Acids Research, 2019, 47, 3086-3100.	6.5	24
33	The various facets of the proteinâ€folding activity of the ribosome. Biotechnology Journal, 2011, 6, 668-673.	1.8	23
34	Mechanism of cystathionine-Î²-synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II). Biochemical Pharmacology, 2020, 182, 114267.	2.0	23
35	Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie, 2011, 93, 1047-1054.	1.3	22
36	Isolation and Characterization of HRT1 Using a Genetic Screen for Mutants Unable to Degrade Gic2p in Saccharomyces cerevisiae. Genetics, 2000, 155, 1033-1044.	1.2	22

#	Article	IF	Citations
37	A single step synthesis of 6-aminophenanthridines from anilines and 2-chlorobenzonitriles. Tetrahedron, 2004, 60, 4705-4708.	1.0	21
38	In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules. Molecules, 2018, 23, 3124.	1.7	21
39	Polyunsaturated fatty acids inhibit PI3K activity in a yeastâ€based model system. Biotechnology Journal, 2009, 4, 1190-1197.	1.8	20
40	Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. Scientific Reports, 2016, 6, 32117.	1.6	19
41	A yeast model for the mechanism of the Epsteinâ€Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness. Microbial Cell, 2017, 4, 305-307.	1.4	18
42	The different activities of RNA G-quadruplex structures are controlled by flanking sequences. Life Science Alliance, 2022, 5, e202101232.	1.3	17
43	An expeditious synthesis of 6-aminophenanthridines. Tetrahedron Letters, 2005, 46, 3725-3727.	0.7	16
44	Tools for the study of ribosomeâ€borne protein folding activity. Biotechnology Journal, 2008, 3, 1033-1040.	1.8	15
45	Guanabenz, an Î±2-selective adrenergic agonist, activates Ca2+-dependent chloride currents in cystic fibrosis human airway epithelial cells. European Journal of Pharmacology, 2008, 592, 33-40.	1.7	15
46	A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion. DMM Disease Models and Mechanisms, 2014, 7, 435-44.	1.2	15
47	A yeast-based screening assay identifies repurposed drugs that suppress mitochondrial fusion and mtDNA maintenance defects. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	15
48	p53, p63 and p73 in the wonderland ofS. cerevisiae. Oncotarget, 2017, 8, 57855-57869.	0.8	15
49	Antiprion Drugs as Chemical Tools to Uncover Mechanisms of Prion Propagation. Prion, 2007, 1, 48-52.	0.9	14
50	Inhibition of RNA Recruitment and Replication of an RNA Virus by Acridine Derivatives with Known Anti-Prion Activities. PLoS ONE, 2009, 4, e7376.	1.1	14
51	Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. European Journal of Medicinal Chemistry, 2014, 82, 363-371.	2.6	13
52	The longâ€lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epsteinâ€Barr virus. Biotechnology Journal, 2015, 10, 1670-1681.	1.8	13
53	Long-Term Fipronil Treatment Induces Hyperactivity in Female Mice. International Journal of Environmental Research and Public Health, 2020, 17, 1579.	1.2	13
54	An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. International Journal of Molecular Sciences, 2020, 21, 4537.	1.8	13

#	Article	IF	Citations
55	Synthesis of Conjugates of 6-Aminophenanthridine and Guanabenz, Two Structurally Unrelated Prion Inhibitors, for the Determination of Their Cellular Targets by Affinity Chromatography. Bioconjugate Chemistry, 2010, 21, 279-288.	1.8	12
56	Artemisinin and its derivatives target mitochondrial c-type cytochromes in yeast and human cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118661.	1.9	12
57	Using yeast to model calcium-related diseases: Example of the Haileyâ€“Hailey disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2315-2321.	1.9	10
58	Procedure for Identification and Characterization of Drugs Efficient Against Mammalian Prion: From a Yeast-Based Antiprion Drug Screening Assay to In Vivo Mouse Models. Infectious Disorders - Drug Targets, 2009, 9, 31-39.	0.4	8
59	The double life of the ribosome: When its protein folding activity supports prion propagation. Prion, 2017, 11, 89-97.	0.9	8
60	Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2297-2307.	1.9	8
61	Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion. Genes, 2019, 10, 667.	1.0	8
62	Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation. Neurotherapeutics, 2021, 18, 1137-1150.	2.1	8
63	Editorial: Fluorescent biosensors. Biotechnology Journal, 2014, 9, 171-173.	1.8	6
64	Evaluation of CDK Inhibitor Selectivity. Enzyme Inhibitors Series, 2006, , 103-119.	0.1	5
65	Editorial: Role of cyclinâ€dependent kinaseâ€5 (Cdk5) in the central nervous system. Biotechnology Journal, 2007, 2, 914-915.	1.8	4
66	Flirting with CFTR modifier genes at happy hour. Genome Medicine, 2012, 4, 98.	3.6	3
67	Quadruplex-interacting compounds for regulating the translation of the Epsteinâ€“Barr virus nuclear antigen 1 (EBNA1) mRNA: A new strategy to prevent and treat EBV-related cancers. Annual Reports in Medicinal Chemistry, 2020, , 243-286.	0.5	2
68	Editorial: RNA-assisted protein folding. Biotechnology Journal, 2008, 3, 967-969.	1.8	1
69	Editorial: Current status and prospects on nucleic acid transfer. Biotechnology Journal, 2014, 9, 1363-1364.	1.8	1
70	A Single Step Synthesis of 6-Aminophenanthridines from Anilines and 2-Chlorobenzonitriles.. ChemInform, 2004, 35, no.	0.1	0
71	An Expeditious Synthesis of 6-Aminophenanthridines.. ChemInform, 2005, 36, no.	0.1	0
72	Editorial: Ready for an orange revolution in biotechnology?. Biotechnology Journal, 2006, 1, 237-238.	1.8	0

#	Article	IF	Citations
73	Editorial: In vivo protein folding - at the crossroad between basic research and biotechnology. Biotechnology Journal, 2011, 6, 615-617.	1.8	0
74	Meeting report: 3rdMeeting of the Biosensor Workgroup of the GDR2588. Biotechnology Journal, 2014, 9, 178-179.	1.8	0